Thioether Patents (Class 514/712)
-
Patent number: 10058419Abstract: Oxidation resistant bioprosthetic tissues and oxidation resistant bioprosthetic heart valve leaflets are described. Also provided are methods for preparing the oxidation resistant bioprosthetic tissues and bioprosthetic heart valve leaflets, and methods for preventing oxidative degeneration in bioprosthetic tissues, including immobilizing covalently an effective amount of an antioxidant to the bioprosthetic tissue.Type: GrantFiled: July 11, 2012Date of Patent: August 28, 2018Assignee: The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Ivan Alferiev, Stanley Stachelek, Jeanne M. Connolly, Abigail Christian
-
Patent number: 9907763Abstract: The present invention relates to a method of treating or preventing the visual function loss in optic nerve in a subject after crush injury by using 4-(Phenylsulfanyl)butane-2-one (4-PSB-2). The present invention has the ability of enhancing the protection effect of RGCs, preserving the visual function in optic nerve after crush injury, recovering the visual function loss, attenuating apoptosis in optic nerve after injury, and inhibiting the inflammatory responses in optic nerves after ON injury.Type: GrantFiled: October 21, 2016Date of Patent: March 6, 2018Assignee: NATIONAL SUN YAT-SEN UNIVERSITYInventors: Shun-Ping Huang, Jyh-Horng Sheu, Zhi-Hong Wen, Rong-Kung Tsai
-
Patent number: 9486400Abstract: A method of improving the appearance of aging skin that includes applying an effective amount of artichoke leaf extract and carob fruit extract in combination to a target area of skin that exhibits a sign of aging skin. The composition is applied for a period of time sufficient to improve the appearance of the aging skin.Type: GrantFiled: June 17, 2013Date of Patent: November 8, 2016Assignee: The Proctor & Gamble CompanyInventors: Rosemarie Osborne, Lisa Ann Mullins, Deborah Ruth Finley
-
Patent number: 9446017Abstract: Green tea polyphenol compositions and methods of their use in treating herpes simplex virus (HSV) are provided. Representative green tea polyphenols include, but are not limited to (?)-epigallocatechin-3-gallate as well as green tea polyphenols with one on more ester-linked fatty acids.Type: GrantFiled: July 6, 2011Date of Patent: September 20, 2016Assignee: Augusta University Research Institute, Inc.Inventor: Stephen D. Hsu
-
Patent number: 9370488Abstract: The embodiments herein provide a long-acting injectable drug (insulin) delivery nano-carrier system and a method of synthesizing the same. The insulin entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer and dissolved insulin. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the formed nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage the nanodispersion is dried to form a powder.Type: GrantFiled: July 21, 2014Date of Patent: June 21, 2016Assignees: Kimia Zist Parsian, TehramInventor: Mehrdad Hamidi
-
Publication number: 20150038468Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.Type: ApplicationFiled: October 20, 2014Publication date: February 5, 2015Inventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
-
Publication number: 20150010638Abstract: It is an object of the present invention to provide a method for improving the solubility of a poorly-soluble substance, which is capable of increasing the solubility of substantially all poorly-soluble substances. This is a method comprising coating the surface of a poorly-soluble substance particle with microparticles of a calcium compound such as calcium phosphate or calcium carbonate, and at least one selected from a pH adjuster and a surfactant, by applying mechanical energy thereto.Type: ApplicationFiled: February 21, 2013Publication date: January 8, 2015Inventors: Shuji Sakuma, Keiichiro Kikukawa, Ryosuke Miyasaka
-
Patent number: 8859819Abstract: The present invention relates to a compound of the general formula (I) where: X?S, SO or SO2; and one of the radicals R1 and R2 is a hydrogen atom and the other is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6 alkoxy group(s); or a COR3 or CONHR3, but not simultaneously, where R3 is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6 alkoxy group(s); an aralkenyl, optionally substituted by one or more C1 to C6 alkoxy groups and/or one or more OH group(s); or an aryl radical, optionally substituted by one or more C1 to C6 alkoxy group(s).Type: GrantFiled: April 8, 2010Date of Patent: October 14, 2014Assignee: Pierre Fabre Dermo-CosmetiqueInventor: Stéphane Poigny
-
Patent number: 8791161Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: GrantFiled: February 20, 2013Date of Patent: July 29, 2014Assignee: Allergan, Inc.Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, John E. Donello, Xiaoxia Liu, Veena Viswanath
-
Publication number: 20140155493Abstract: Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described.Type: ApplicationFiled: February 10, 2014Publication date: June 5, 2014Applicant: THE UAB RESEARCH FOUNDATIONInventor: Ahmad Safavy
-
Patent number: 8741966Abstract: The present disclosure relates to lipid compounds of formula (I): wherein: R1 is chosen from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and are chosen from hydrogen and a C1-C6 alkyl; X is chosen from O, S, SO, SO2, Si, and Se; n=1 or 3; and P1 is chosen from hydrogen; a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; a group of formula (II) or formula (III), wherein P2, P3, and P4 are chosen from hydrogen, an alkyl, an alkenyl, and an alkynyl, optionally substituted; and a group of formula (IV) or formula (V), wherein P5 is chosen from hydrogen and a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex, or solvate thereof.Type: GrantFiled: November 6, 2008Date of Patent: June 3, 2014Assignee: Pronova Biopharma Norge ASInventor: Anne Kristin Holmeide
-
Patent number: 8734769Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: GrantFiled: March 8, 2013Date of Patent: May 27, 2014Assignee: The Brigham and Women's Hospital, Inc.Inventor: Richard T. Lee
-
Patent number: 8722745Abstract: The invention relates to a sulfur-containing compound and the preparation thereof. The invention also relates to the uses of the sulfur-containing compound in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. This invention also describes a series of chemical analogues of the said sulfur-containing compound and the preparation of these compounds.Type: GrantFiled: February 6, 2013Date of Patent: May 13, 2014Assignee: National Sun Yat-Sen UniversityInventors: Jyh-Horng Sheu, Chih-Hua Chao, Zhi-Hong Wen
-
Publication number: 20130338117Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.Type: ApplicationFiled: August 27, 2013Publication date: December 19, 2013Applicant: The Trustees of the University of PennsylvaniaInventor: Robert P. RICCIARDI
-
Patent number: 8609704Abstract: A personal care composition which contains 25-200 ppm of 2-methyl-4-isothiazolin-3-one and at least one hydroquinone radical scavenger, and a method for reducing odor arising in personal care compositions containing 2-methyl-4-isothiazolin-3-one.Type: GrantFiled: July 10, 2009Date of Patent: December 17, 2013Assignee: Rohm and Haas CompanyInventors: Thu-Ba Thi Tran, Janet Nadya Younathan
-
Patent number: 8609076Abstract: The present invention relates to the use of polyols of formula (I): or a salt thereof, for preventing the hair from breaking. The invention also relates to a cosmetic composition comprising at least one such polyol or a salt thereof, in a cosmetically acceptable medium, and also to a cosmetic hair treatment process using the said composition.Type: GrantFiled: May 13, 2005Date of Patent: December 17, 2013Assignee: L'OrealInventors: Frederic Leroy, Michel Philippe, Philippe Barbarat, Christian Blaise
-
Publication number: 20130274344Abstract: The presently disclosed and claimed inventive concept(s) provides new estrogenic compounds of the general formula and pharmaceutical compositions containing them. The compounds of the presently disclosed and claimed inventive concept(s) are useful, for example, in hormone replacement therapies (HRT/ERT), and as contraceptives, and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the presently disclosed and claimed inventive concept(s).Type: ApplicationFiled: June 7, 2013Publication date: October 17, 2013Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim, Christine Pratt
-
Publication number: 20130251664Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 8, 2013Publication date: September 26, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Richard T. Lee
-
Publication number: 20130243886Abstract: The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an a-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.Type: ApplicationFiled: September 9, 2011Publication date: September 19, 2013Applicant: HELPERBY THERAPEUTICS LIMITEDInventors: Yanmin Hu, Anthony RM Coates
-
Patent number: 8507545Abstract: Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease. An EP4 agonist exhibits an immunopotentiating activity through the activation of a cytotoxic T cell, and is therefore useful for the prevention and/or treatment of cancer or a microorganism-mediated infection disease.Type: GrantFiled: May 7, 2008Date of Patent: August 13, 2013Assignees: National University Corporation, Hamamatsu University School of Medicine, Ono Pharmaceutical Co., Ltd.Inventors: Masahiro Takigawa, Naohiro Seo, Kenji Kabashima, Takayuki Maruyama, Toshiya Kanaji
-
Publication number: 20130123326Abstract: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.Type: ApplicationFiled: January 4, 2013Publication date: May 16, 2013Applicants: REGION MIDTJYLLAND, AARHUS UNIVERSITETInventors: AARHUS UNIVERSITET, REGION MIDTJYLLAND
-
Publication number: 20130109758Abstract: This invention provides compounds having a structure of Formula (I). Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: January 6, 2011Publication date: May 2, 2013Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
-
Publication number: 20130035304Abstract: This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 31, 2011Publication date: February 7, 2013Inventors: Loren D. Walensky, Michelle L. Stewart, Nicole Cohen
-
Patent number: 8367737Abstract: The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadinc, Perphenazine, Bithionol, and Clomipramine.Type: GrantFiled: April 14, 2008Date of Patent: February 5, 2013Assignee: Southern Research InstituteInventors: Zhican Qu, Anshu M. Roy, Subramaniam Ananthan
-
Patent number: 8357701Abstract: Therapeutic agents for treatment of Galactosemia and disorders thereof, and other enzyme related disorders thereof are identified. The compounds inhibit galactokinase (GALK) and other kinase activity and are identified by a high throughput screening assay.Type: GrantFiled: August 14, 2008Date of Patent: January 22, 2013Assignee: University of MiamiInventors: Kent Lai, Klass Jan Wierenga, Manshu Tang
-
Publication number: 20130005718Abstract: Compositions and methods for managing or treating chronic pain are provided. More particularly, methods are provided for managing or treating chronic pain by administering to a patient in need thereof an effective amount of propofol or a propofol derivative having limited anesthetic properties. Methods of modulating HCN channel gating are also provided. Pharmaceutically acceptable compositions for, e.g., modulating HCN channel gating are further provided.Type: ApplicationFiled: August 10, 2010Publication date: January 3, 2013Inventors: Gareth R. Tibbs, Pamela Flood, Peter Goldstein
-
Publication number: 20120328541Abstract: Compounds of the formulae and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of the formula wherein G1 is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9-phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9-phenylalkyl; E is oxyl or hydroxyl; V is —O—; or —NH—; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.Type: ApplicationFiled: September 5, 2012Publication date: December 27, 2012Inventors: Werner Baschong, Oliver Reich, Sébastien Mongiat
-
Publication number: 20120322770Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.Type: ApplicationFiled: August 21, 2012Publication date: December 20, 2012Inventor: Robert P. RICCIARDI
-
Patent number: 8304455Abstract: The present invention relates to compositions and methods for treating, preventing and improving the condition and/or aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include active agents which increase expression levels of genes associated with the dermatological signs of aging. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof, once daily in an amount effective in improving the condition and/or aesthetic appearance of skin.Type: GrantFiled: February 4, 2008Date of Patent: November 6, 2012Assignee: Avon Products, IncInventors: Laurence Dryer, Dmitri Ptchelintsev
-
Patent number: 8278349Abstract: Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed.Type: GrantFiled: November 6, 2006Date of Patent: October 2, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Liat Goldberg, Michael Brownstein
-
Patent number: 8268889Abstract: Disclosed are methods of treating ovarian cancer by administering an effective amount of FTS (farnesylthiosalicylic acid), or various analogs thereof, or a pharmaceutically acceptable salt, optionally with, a platinum-based chemotherapy drug to a human diagnosed with ovarian cancer.Type: GrantFiled: February 1, 2007Date of Patent: September 18, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Gilad Ben-Baruch
-
Publication number: 20120213838Abstract: The present invention provides a medical device for placement into a lumen such as a stent and a catheter whose surface is uniformly and sufficiently coated with a drug, and a process thereof with easy way and with low cost. The medical device is coated with mixed particles of drug particles whose surface is modified with positive-charge and biocompatible nanoparticles. In the invention, a drug can be taken into a cell through the dissolution of the drug particle together with the biocompatible nanoparticle after a DES is placed in a biological body.Type: ApplicationFiled: August 26, 2010Publication date: August 23, 2012Inventors: Kensuke Egashira, Hiroyuki Tsujimoto, Kaori Hara, Yusuke Tsukada, Yohei Bando, Matsuya Manabe
-
Patent number: 8247458Abstract: A therapeutic agent for the treatment of diabetic neuropathy which comprises (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]-ethyl]dimethylsulfonium p-toluenesulfonate of the formula (1) as an active ingredient.Type: GrantFiled: December 20, 2007Date of Patent: August 21, 2012Assignee: Taiho Pharmaceutical Co., Ltd.Inventor: Mamoru Kiniwa
-
Patent number: 8247595Abstract: There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R1 represents a C3-C10 alkenyl group optionally substituted with at least one halogen atom, a C3-C10 alkynyl group optionally substituted with at least one halogen atom, or the like, R2 represents a cyano group or the like, R3 represents a hydrogen atom, a halogen atom or a C1-C4 alkyl group, R4 represents a C1-C5 fluoroalkyl group, and n represents 0, 1 or 2.Type: GrantFiled: May 16, 2008Date of Patent: August 21, 2012Assignee: Sumitomo Chemical Company, LimitedInventor: Hiroyuki Miyazaki
-
Publication number: 20120135971Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.Type: ApplicationFiled: January 18, 2012Publication date: May 31, 2012Inventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
-
Publication number: 20120095048Abstract: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.Type: ApplicationFiled: February 19, 2010Publication date: April 19, 2012Applicants: REGION MIDT JYLLAND, AARHUS UNIVERSITETInventors: Henrik Amtoft Neubauer, Ove Kjaer Wiborg, Henrik Helligsø Jensen
-
Publication number: 20120034176Abstract: The present invention relates to a compound of the general formula (I) where: X?S, SO or SO2; and one of the radicals R1 and R2 is a hydrogen atom and the other is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6alkoxy group(s); or a COR3 or CONHR3, but not simultaneously, where R3 is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6alkoxy group(s); an aralkenyl, optionally substituted by one or more C1 to C6 alkoxy groups and/or one or more OH group(s); or an aryl radical, optionally substituted by one or more C1 to C6 alkoxy group(s).Type: ApplicationFiled: April 8, 2010Publication date: February 9, 2012Applicant: PIERRE FABRE DERMO-COSMETIQUEInventor: Stéphane Poigny
-
Publication number: 20120015960Abstract: Provided are compounds for inhibiting Snail-p53 binding and therapeutic agents for cancer including the compounds as an effective component. The Snail-p53 binding inhibitors induce expression of p53 in K-Ras mutant cell lines, thereby enabling effective treatment or prevention of K-Ras mutant cancer, such as, pancreatic cancer, lung cancer, cholangioma, and colon cancer, of which diagnosis or treatment is not easy.Type: ApplicationFiled: November 23, 2009Publication date: January 19, 2012Applicants: The Industry & Academic Cooperation in Chungnam National University, Pusan National University Industry-University Cooperation FoundationInventors: Bum Joon Park, Nam Chul Ha, Sun Hye Lee, Gyu Yong Song, Jee Hyun Lee
-
Publication number: 20110319349Abstract: Methods and compositions for the treatment or prophylaxis of a disorder associated with platelet activation or enhanced thrombin activity are provided, that include the administration of an effective amount of a compound of the formula: or its pharmaceutically acceptable salt, ester or prodrug, wherein the substituents are defined herein, optionally in the appropriate pharmaceutically acceptable carrier for the route of administration selected.Type: ApplicationFiled: September 6, 2011Publication date: December 29, 2011Inventors: Robert A.D. Scott, Victor Serebruany
-
Publication number: 20110251236Abstract: Therapeutic agents for treatment of Galactosemia and disorders thereof, and other enzyme related disorders thereof are identified. The compounds inhibit galactokinase (GALK) and other kinase activity and are identified by a high throughput screening assay.Type: ApplicationFiled: August 14, 2008Publication date: October 13, 2011Applicant: University of MiamiInventors: Kent Lai, Klass Jan Wierenga, Manshu Tang
-
Publication number: 20110196045Abstract: The present invention provides new estrogenic compounds of the general formula in which the substituents have the meanings that are explained in more detail in the description, and pharmaceutical compositions containing them. The compounds of the invention are useful, for example, in hormone replacement therapies (HRT/ERT) and as contraceptives and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the invention.Type: ApplicationFiled: April 21, 2011Publication date: August 11, 2011Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim
-
Publication number: 20110152263Abstract: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia. The composition contains a therapeutically effective amount of a binding-inhibiting compound selected from Compounds 1 through 15, and at least one diluent, carrier or excipient. The Compounds competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions can be administered to a human prior to or after infection by a Norovirus, to prevent or ameliorate an infection.Type: ApplicationFiled: November 15, 2007Publication date: June 23, 2011Inventor: Xi JIANG
-
Publication number: 20110110886Abstract: Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned media of human melanoma cells that stimulates a myriad of biological activities including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin embedded human tissue demonstrates that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small molecule inhibitors with binding constants ranging from nanomolar to low micromolar.Type: ApplicationFiled: June 15, 2009Publication date: May 12, 2011Inventor: Demetrios Braddock
-
Publication number: 20110065703Abstract: The present invention includes a group of chemical compounds useful as modulators of calcium ion (Ca2+) channels, especially for T-type, N-Type and L-type channels. The present invention also includes pharmaceutical compositions comprising these calcium ion channel modulating agents and methods of using these calcium ion channel modulating agents for the treatment diseases and conditions associated with the calcium ion channels.Type: ApplicationFiled: March 12, 2008Publication date: March 17, 2011Inventor: Jay Jie-Qiang Wu
-
Publication number: 20110054037Abstract: Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described.Type: ApplicationFiled: April 6, 2009Publication date: March 3, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventor: Ahmad Safavy
-
Publication number: 20100280109Abstract: The present disclosure relates to lipid compounds of formula (I): wherein: R1 is chosen from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and are chosen from hydrogen and a C1-C6 alkyl; X is chosen from O, S, SO, SO2, Si, and Se; n=1 or 3; and P1 is chosen from hydrogen; a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; a group of formula (II) or formula (III), wherein P2, P3, and P4 are chosen from hydrogen, an alkyl, an alkenyl, and an alkynyl, optionally substituted; and a group of formula (IV) or formula (V), wherein P5 is chosen from hydrogen and a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex, or solvate thereof.Type: ApplicationFiled: November 6, 2008Publication date: November 4, 2010Inventor: Anne Kristin Holmeide
-
Publication number: 20100247462Abstract: Processes for synthesizing resveratrol-based oligomers are provided. In addition, resveratrol-based oligomer compounds free of plant extract are provided.Type: ApplicationFiled: September 17, 2008Publication date: September 30, 2010Inventors: Scott Alan Snyder, Steven P. Breazzano, Audrey G. Ross, Yunqing Lin, Alexandros L. Zografos
-
Publication number: 20100222406Abstract: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R1 is selected from the group consisting of C1-C4 alkyl, hydroxy and C1-C4 alkoxy; X is selected from the group consisting of N and CH; Z is selected from the group consisting of NH, O, S and CH2; R2 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy; and R3 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy.Type: ApplicationFiled: January 14, 2010Publication date: September 2, 2010Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Lloyd S. Gray, Doris M. Haverstick
-
Publication number: 20100216689Abstract: Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease. An EP4 agonist exhibits an immunopotentiating activity through the activation of a cytotoxic T cell, and is therefore useful for the prevention and/or treatment of cancer or a microorganism-mediated infection disease.Type: ApplicationFiled: May 7, 2008Publication date: August 26, 2010Applicants: ONO PHARMACEUTICAL CO., LTD.Inventors: Masahiro Takigawa, Naohiro Seo, Kenji Kabashima, Takayuki Maruyama, Toshiya Kanaji
-
Patent number: 7781488Abstract: The present invention provides a method and compositions for synthesizing an oligopeptide or polypeptide by convergent assembly of a plurality of pairs of oligopeptides in chemical ligation reactions. An important aspect of the present invention is an oligopeptide having a C-terminal disulfide-protected carboxythioester group that can be deprotected to spontaneously generate a free C-terminal thioester moiety. This allows a single precursor to participate in a succession of chemical ligation reactions, thereby making the convergent synthesis approach possible. The present invention is useful in methods for chemical synthesis of oligopeptides, polypeptides and proteins, and improves the efficiency of native chemical ligation reactions, particularly where four or more peptide fragments are used to assemble an oligopeptide, polypeptide or protein product.Type: GrantFiled: June 9, 2003Date of Patent: August 24, 2010Assignee: Amylin Pharmaceuticals, Inc.Inventors: Paolo Botti, Matteo Villain, Sonia Manganiello, Hubert Gaertner